相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Dinesh Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2020)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Imre Noth et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
K. R. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Antonella Caminati et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Elizabeth R. Volkmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Low starting-dosage of nintedanib for the reduction of early termination
Satoshi Ikeda et al.
RESPIRATORY INVESTIGATION (2019)
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
Frank Hilberg et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Treatment Algorithms for Systemic Sclerosis According to Experts
Andreu Fernandez-Codina et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Martin Kolb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
Vincent Cottin et al.
EUROPEAN RESPIRATORY REVIEW (2018)
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis
Oliver Distler et al.
RESPIRATORY MEDICINE (2017)
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
Satoshi Ikeda et al.
SCIENTIFIC REPORTS (2017)
Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities
John Varga et al.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2017)
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis
Jingang Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Mapping and predicting mortality from systemic sclerosis
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pulmonary hypertension in systemic sclerosis: different phenotypes
David Launay et al.
EUROPEAN RESPIRATORY REVIEW (2017)
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Jingang Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Masataka Kuwana et al.
JOURNAL OF RHEUMATOLOGY (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling
Ada Man et al.
RHEUMATOLOGY (2015)
Cardiomyopathy in Murine Models of Systemic Sclerosis
Paulius Venalis et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis How Similar and Distinct?
Erica L. Herzog et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Pulmonary hypertension in chronic interstitial lung diseases
Antonella Caminati et al.
EUROPEAN RESPIRATORY REVIEW (2013)
Mutant Soluble Ectodomain of Fibroblast Growth Factor Receptor-2 IIIc Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Zhi-hong Yu et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
M. Reck et al.
ANNALS OF ONCOLOGY (2011)
Idiopathic pulmonary fibrosis
Talmadge E. King et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
Kohtaro Abe et al.
CIRCULATION (2010)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1
Robert Eferl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice
N Hamada et al.
JOURNAL OF IMMUNOLOGY (2005)
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice
Y Aono et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
A Abdollahi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Regulation of PDGF and its receptors in fibrotic diseases
JC Bonner
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
VJ Thannickal et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis
Y Inoue et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
分享论文
